High-dose chemotherapy combined with autologous peripheral blood stem cell transplantation has shown promise as treatment for recurrent or persistent epithelial ovarian cancer. We evaluated the stem cell mobilization regimen of high-dose ifosfamide plus etoposide in 32 patients with epithelial ovarian cancer, who had a positive second-look laparatomy or recurrent disease. Ifosfamide was given at 10 g/m 2 by continuous i.v. from days 1 to 3. Etoposide was given at 150 mg/m 2 every 12 h for six doses on days 1-3. Filgrastim was given at 10 g/kg/d s.c. from day 5 until the completion of peripheral blood stem cell harvest. Fourteen of 32 patients had measurable or evaluable disease before mobilization therapy and were assessed for response. In nine (64%) of the 14 patients, treatment response was demonstrated, and these patients received a second cycle of mobilization therapy. The target CD34
Summary:
High-dose chemotherapy combined with autologous peripheral blood stem cell transplantation has shown promise as treatment for recurrent or persistent epithelial ovarian cancer. We evaluated the stem cell mobilization regimen of high-dose ifosfamide plus etoposide in 32 patients with epithelial ovarian cancer, who had a positive second-look laparatomy or recurrent disease. Ifosfamide was given at 10 g/m 2 by continuous i.v. from days 1 to 3. Etoposide was given at 150 mg/m 2 every 12 h for six doses on days 1-3. Filgrastim was given at 10 g/kg/d s.c. from day 5 until the completion of peripheral blood stem cell harvest. Fourteen of 32 patients had measurable or evaluable disease before mobilization therapy and were assessed for response. In nine (64%) of the 14 patients, treatment response was demonstrated, and these patients received a second cycle of mobilization therapy. The target CD34
+ cell dose (Ͼ8 × 10 6 cells/kg) was achieved with a median of one apheresis (range 1-5). A median of 25.1 (range 8.0-122.5) × 10 6 CD34 + cells/kg body weight was collected. Non-hematologic toxicity was limited to grade 2 renal dysfunction in one patient and grade 2 hepatic dysfunction in three patients. In this patient group, high-dose ifosfamide plus etoposide with filgrastim support was well tolerated, lead to successful stem cell harvest and had antitumor activity. Bone Marrow Transplantation (2000) 25, 1137-1140. Keywords: ovarian cancer; stem cell collection; ifosfamide; etoposide Patients with recurrent or persistent epithelial ovarian cancer have a poor prognosis and there are few long-term survivors. In recent studies, 1,2 treatment with high-dose chemotherapy and peripheral blood stem cell (PBSC) or bone marrow transplantation has shown promising results in selected patients. In a study by Stiff et al, 2 patients with recurrent, platinum-sensitive disease had approximately a 33% 5-year survival rate with this treatment approach. Transplantation of autologous PBSC is generally associated with more rapid hematological recovery than transplantation of bone marrow. [3] [4] [5] Many studies have indicated that hematopoietic recovery is related to the number of CD34 + cells infused and suggest a target of 2-5 × 10 6 CD34
+ cells/kg body weight for a single myeloablative intensification cycle. 6, 7 PBSCs are commonly harvested during cytokine treatment 6 at the time of recovery of peripheral blood counts from chemotherapy. 8 The ideal stem cell mobilization regimen allows successful stem cell harvest with a minimum number of aphereses, is well tolerated, and produces effective antitumor activity. Cyclophosphamide, in doses ranging from 3 to 7 g/m 2 is the agent most commonly used for stem cell mobilization. [9] [10] [11] In recent years, investigators have combined cyclophosphamide with paclitaxel with promising results. 12 In this study, we evaluated a regimen of high-dose ifosfamide plus etoposide with filgrastim for PBSC mobilization in patients with advanced ovarian cancer. The aim was to assess the stem cell yield, hematologic and non-hematologic toxicities, and overall antitumor activity produced by this regimen.
Patients and methods

Patients
Between October 1997 and March 1999, we studied 32 patients with epithelial ovarian cancer who were undergoing stem cell mobilization and apheresis ( Table 1) . Most of the patients were enrolled in a phase I trial of high-dose chemotherapy and autologous stem cell transplantation for the treatment of ovarian cancer. Patients were eligible for our study if they had invasive epithelial ovarian cancer with recurrent disease or a positive second-look laparotomy. Prior to enrollment in the study, all patients with recurrent disease were reinduced with standard-dose chemotherapy until maximal response was achieved. Response to reinduction chemotherapy was not required. However, in all patients, the largest tumor mass could not exceed 2 cm. Following standard-dose salvage chemotherapy or second-look surgery and immediately prior to initiation of the ifosfamide/etoposide regimen, 10 patients had progressive disease, three had stable disease, eight were in partial remission, and 11 were in complete clinical remission (CR). Of the 11 patients in clinical CR, six had had a positive second-look laparatomy and five were in second or greater CR following standard-dose salvage chemotherapy. Two of the 32 patients had received prior stem cell transplantation. The median number of prior chemotherapy regimens per patient was two (range 1-4). All patients had received at least six cycles of platinum and paclitaxel.
Treatment plan
For PBSC mobilization and pretransplant cytoreduction, patients received ifosfamide at 10 g/m 2 (total dose) by continuous i.v. over 72 h (days 1-3) and etoposide at 150 mg/m 2 in 2 h i.v. infusions every 12 h during the same 72 h period (for a total of six doses). Filgrastim was given at 5 g/kg twice a day s.c. from day 5 until completion of stem cell harvest. Mesna was given at 2 g/m 2 by i.v. infusion before and at the completion of the ifosfamide. Mesna also was given at 8 g/m 2 by i.v. infusion concomitant with the ifosfamide infusion ( Table 2 ). Patients were also given oral prophylactic antibiotics consisting of penicillin, norfloxacin, valacyclovir, and fluconazole starting on day 5.
Patients were hospitalized during the administration of the mobilization regimen and discharged after the final dose of mesna. Patients who demonstrated a clinical response to this treatment could receive a second cycle of ifosfamide/etoposide followed by filgrastim 5 g/kg once /l, twice their blood volume was processed. Venous access was established via a Mahurkar dual-lumen hemodialysis catheter (Quinton Instrument, Bothell, WA, USA) and anticoagulant citrate dextrose (ACD-A) solution was used to prevent clotting. The CD34
+ cell content of the collection product was measured immediately after apheresis. The cells were subsequently cryopreserved using programmed freezing. The apheresis products and the CD34 + cell concentration were analyzed by two-color flow cytometry. A Hewlett-Packard 340 computer system and LYSYS-II software (Becton Dickinson Immunocytometry, San Jose, CA, USA) were used for acquisition of total events and analysis of the list-mode data. From a dot plot of forward and 90°light scatter, a gate was established to include all lymphocytes and monocytes, excluding granulocytes. Quadrant statistics were obtained from a two-axis dot plot (CD34 + and CDw90) to obtain the percentage of CD34 
Statistical methods and definition of response
All analyses were performed using Statistica for Windows Release 5.1 (StatSoft, Tulsa, OK, USA). Patients were considered to have measurable disease if they had tumor that could be measured in two dimensions by imaging scans or physical examination. Patients were considered to have evaluable disease if they had no measurable disease on scans or physical examination but had an elevated serum CA-125 level (Ͼ40 U/ml) in two samples. Response to treatment for patients with measurable disease was determined according to the World Health Organization response criteria. 13 Response to treatment for patients with evaluable disease was based on CA-125 serum levels, as described by Rustin et al 14 and Bridgewater et al 15 :
(1) A 50% response is declared if there is a 50% decrease in CA-125 serum levels. There must be two initial samples, and the sample showing a 50% decrease must be confirmed by a fourth sample. (2) A 75% response is declared if there has been a serial decrease of Ͼ75% in CA-125 serum levels over three samples.
Results
Patients
A total of 32 patients was enrolled in this study, and a total of 41 cycles of ifosfamide/etoposide was given. All patients were assessed for stem cell yield and regimen toxicity. Fourteen patients had measurable (12 patients) or evaluable (two patients) disease and, thus, were assessed for response. Thirty-one of the 32 patients went on to receive high-dose chemotherapy with stem cell infusion as planned. Only one patient had disease progression after mobilization therapy; this patient was taken off the study.
Apheresis data
Stem cell collection was initiated a median of 14 days (range 11-21 days) from the start of chemotherapy (Table 3) . A median of 1 day (range 1-5 days) was needed to reach the target CD34
+ cell count of у8 × 10 6 /kg, enough for two intensification cycles. Pre-apheresis periphal blood CD34
+ cell count was used to help guide the start of apheresis. A median of 25.1 (range 8.0-122.5) × 10 6
CD34
+ cells/kg body weight was collected, with a mean of 16.0 × 10 6 CD34 + cells/kg per apheresis.
Toxicity data
The ifosfamide/etoposide regimen was well tolerated. Using the National Cancer Institute Common Toxicity criteria, 16 grade 2 nausea/vomiting was observed in three patients. Grade 2 nephrotoxicity presenting as a transient rise in creatinine level was seen in one patient. Three patients had a transient rise in their liver enzymes (grade 2). There was no neurotoxicity. Nine (22%) episodes of neutropenic fever occurred during the 41 cycles of mobilization therapy. The median time to recovery of an absolute nucleated cell count of Ͼ1 × 10 9 /l was 13 days (range 11-26 days). The median time to recovery of platelet counts of Ͼ20 × 10 9 /l and Ͼ50 × 10 9 /l was 12 days (range 0-21 days) and 15 days (range 0-37 days), respectively. A median of 0 (range 0-3) platelet transfusions was required. A median of 0 (range 0-2) PBSC transfusions was required (Table 3) . Thirty-seven percent of the cycles required patients to receive packed red blood cell transfusions and, in 44% of the cycles, platelet transfusions were required.
Tumor response
Fourteen (44%) of the 32 patients had measurable or evaluable disease and, thus, were assessed for response. Patients were assessed by serum CA-125 level, by computed tomo- , and two had a Ͼ75% response based on CA-125 criteria (both patients had normalization of serum CA-125 levels). Seven of the nine responders had been refractory to standard-dose reinduction chemotherapy. Of the five nonresponders, four had stable disease or minor response (28.5%), and in one patient, the disease progressed (7%).
Discussion
Ifosfamide, a cyclophosphamide analogue, has been previously evaluated at modest doses as treatment for patients with epithelial ovarian cancer. As a single agent in the salvage setting, ifosfamide is associated with a response rate of 10-20%. 17, 18 In other tumor types such as lymphoma and sarcoma, ifosfamide has been shown to have a significant dose-response relationship. The experience with high-dose ifosfamide comes mostly from studies done in patients with soft tissue or bone sarcomas where doses of up to 14 g/m 2 with filgrastim have been used successfully without the need for PBSC support. 19 Etoposide is a glycosidic derivative of epidophyllotoxin previously shown to be associated with a dose-related cell cycle perturbation in ovarian cancer cell lines. 20 Prolonged exposure to oral etoposide has demonstrated significant activity. 21 Intravenous etoposide has been studied as a single agent with response rates lower than 25%. These studies used overall low doses of etoposide: 300 mg/m 2 was given in the largest Gynecologic Oncology Group study. [22] [23] [24] Given the potential dose-response relationship for both ifosfamide and etoposide, we evaluated the antitumor effect that occurs when these drugs are combined and used at their maximal tolerated doses with growth factor support.
A few studies have demonstrated the feasibility of harvesting PBSCs upon recovery from an ifosfamide-based regimen. Baars et al 25 have demonstrated that standard-dose ifosfamide (3-4 g/m 2 ) in combination with etoposide can be successfully used as a mobilization regimen in patients with lymphoma or solid tumors. Our aims in the present study were to cytoreduce patients prior to high-dose chemotherapy and to successfully harvest PBSC. The combination of ifosfamide 10 g/m 2 and etoposide 900 mg/m 2 was associated with mild non-hematologic toxicity. Only one transient renal toxicity was observed in the group studied, and no neurotoxicity was observed. Myelosuppression was significant, as expected with a mobilization regimen. However, most of the patients did not require blood product transfusions and were ready for PBSC harvest within 2 weeks of mobilization chemotherapy. All patients achieved the targeted stem cell dose, with a median of one apheresis per patient.
The overall response rate of 64% in mostly platinumrefractory patients compares favorably with other secondline regimens and suggests a dose-response relationship for these drugs. Commonly used second-line chemotherapeutic agents such as liposomal doxorubicin 26 or topotecan 27 offer expected responses of 13-26%.
In conclusion, high-dose ifosfamide plus etoposide with filgrastim was associated with acceptable non-hematologic toxicity and led to successful PBSC harvest in the patients studied. For patients in whom an aggressive treatment approach is sought, the ifosfamide/etoposide regimen might be an effective alternative to single-agent salvage therapy. However, further evaluation of this treatment option through controlled trials is needed.
